Ubamatamab (REGN4018): A Bispecific Antibody Targeting MUC16 and CD3 for Cancer Immunotherapy

I. Introduction to Ubamatamab (REGN4018)

A. Overview as an Investigational Bispecific Antibody

Ubamatamab, also known by its development code REGN4018, is an investigational, humanized bispecific monoclonal antibody (mAb) engineered for cancer immunotherapy.[1] As a T-cell engager, Ubamatamab is designed to redirect a patient's own T-lymphocytes to identify and eliminate malignant cells. The core of its design lies in its bispecific nature, which enables it to concurrently bind to two different antigens: one expressed on the surface of tumor cells and another on T-cells. This dual binding capacity effectively creates an immunological bridge, forcing a close proximity between the effector T-cells and their target cancer cells, a mechanism intended to potentiate a focused and powerful cytotoxic immune response.[2] This approach represents a significant strategy in immuno-oncology, aiming to overcome tumor immune evasion by directly facilitating T-cell engagement and subsequent tumor cell lysis.

B. Developer and Origin

Ubamatamab (REGN4018) was originated and is under development by Regeneron Pharmaceuticals, Inc..[2] While some historical documentation may link REGN4018 to Sanofi [33], this likely reflects broader historical antibody collaboration agreements between the two companies; current active development and reporting are predominantly attributed to Regeneron. The development of Ubamatamab underscores Regeneron's commitment to advancing its pipeline of bispecific antibodies, leveraging its technological expertise in antibody engineering.[25]

C. Key Identifiers and Physicochemical Properties

Ubamatamab is characterized by specific identifiers and properties, summarized below:

Table 1: Ubamatamab - Key Identifiers and Properties